GAMMA Investing LLC Purchases 865 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 622.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,004 shares of the biopharmaceutical company’s stock after buying an additional 865 shares during the period. GAMMA Investing LLC’s holdings in Ultragenyx Pharmaceutical were worth $47,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. increased its holdings in shares of Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. Covestor Ltd increased its stake in Ultragenyx Pharmaceutical by 392.1% during the 3rd quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 596 shares in the last quarter. Van ECK Associates Corp raised its holdings in Ultragenyx Pharmaceutical by 34.0% during the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 400 shares during the period. International Assets Investment Management LLC lifted its stake in Ultragenyx Pharmaceutical by 3,182.4% in the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 1,623 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 38.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock valued at $95,000 after buying an additional 548 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Bank of America dropped their target price on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Stifel Nicolaus upped their price target on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research report on Friday, May 31st. Wedbush lifted their price objective on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Friday, May 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $115.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 12th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $86.71.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The stock was sold at an average price of $41.10, for a total transaction of $71,390.70. Following the completion of the sale, the director now owns 7,248 shares of the company’s stock, valued at $297,892.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the transaction, the executive vice president now owns 57,981 shares in the company, valued at approximately $2,609,145. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the transaction, the director now directly owns 7,248 shares of the company’s stock, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold a total of 11,685 shares of company stock valued at $518,923 in the last ninety days. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $39.42 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $31.52 and a 52-week high of $54.56. The firm has a 50-day moving average of $41.48 and a 200-day moving average of $45.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The firm had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.33) EPS. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.47 earnings per share for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.